No Prescription |
 |
 | ||
|
Galvus Met Zomarist |
|
| ||
No Prescription » Prescription Drugs 8 » Galvus Met Zomarist Zomarist is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. Buy Galvus Met Zomarist and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Galvus Met Zomarist: Product Type: Prescription Drugs 8 Galvus Met ( Zomarist Generic Vildagliptin/Metformin ) Product Origin: Switzerland Galvus Met (Zomarist Generic Vildagliptin/Metformin) Zomarist Generic Vildagliptin/Metformin 50/1000mg 60 Tablets 120(2 x 60 Tablets) 240(4 x 60 Tablets) Zomarist Generic Vildagliptin/Metformin Galvus Met
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
